---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009826"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:46.042634+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio licenses taletrectinib to Eisai for up to €195M; Q4 IBTROZI rev $15.7M

## Summary
- Exclusive license to Eisai for taletrectinib in EU, Canada, Australia, Middle East, India, others; upfront €50M, up to €145M milestones, royalties up to high-teens.
- Preliminary Q4 IBTROZI net revenue $15.7M; total $24.7M since June 2025 launch; 432 new patient starts.
- Preliminary cash $529.2M at Dec 31, 2025; received $25M milestone from Nippon Kayaku.
- MAA for taletrectinib in Europe expected H1 2026; first €25M milestone upon EU approval.
- Company continues enrollment of safusidenib phase 3 study in IDH1-mutant gliomas; full FY2025 results due March 2026.

## SEC filing metadata
- accession: 0001193125-26-009826
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/0001193125-26-009826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009826
- JSON: https://secwatch.observer/filing/0001193125-26-009826.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009826.txt

## Key facts
- Material Agreements
  Nuvation Bio Inc. entered into License Agreement with Eisai Co., Ltd. valued at €50 million (effective 2026-01-11).
  - Action: entry
  - Agreement: license
  - Counterparty: Eisai Co., Ltd.
  - Value: €50 million
  - Effective: 2026-01-11
  source text: On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/0001193125-26-009826-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.